
Scottish Medicines Consortium





www.scottishmedicines.org.uk

Delta House 50 West Nile Street Glasgow G1 2NP Tel 0141 225 6999 Chairman: Professor Jonathan G Fox

Product Update

posaconazole 100mg gastro-resistant tablets (Noxafil®)

SMC No. (999/14)

MSD Limited

05 September 2014

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

posaconazole tablets (Noxafil®) is accepted for restricted use within NHS Scotland.

Indication under review: in the treatment of the following fungal infections in adults:

- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;
- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;
- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;
- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.

for prophylaxis of invasive fungal infections in the following patients:

- Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;
- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.

SMC restriction: to patients in whom there is a specific risk of *Aspergillus* infection or where fluconazole or itraconazole are not tolerated on the advice of local microbiologists or specialists in infectious diseases.

Posaconazole plasma concentrations are generally higher following administration of posaconazole tablets than posaconazole oral suspension. The tablet and oral suspension are therefore not to be used interchangeably. While the tablets are cost saving when administered for treatment they are significantly more expensive than the oral suspension when administered for prophylaxis.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 15 August 2014.

Chairman Scottish Medicines Consortium